CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

76-200

CHEMISTRY REVIEW(S)

ANDA ~~TENTATIVE~~ APPROVAL SUMMARY

ANDA: #76-200

DRUG PRODUCT: Acetaminophen ER

FIRM: CorePharma LLC
215 Wood Avenue
Middlesex, NJ 08846

DOSAGE FORM: Tablet; Oral
STRENGTH: 650 mg

CGMP STATEMENT/EIR UPDATE STATUS:

Certifications of CGMP (p. 2043) and of section 306(k) (p. 3011) compliance statement are included.

An acceptable EER was issued on 11/13/01.

Facilities included:

Manufacturing, processing, testing and stability testing of Tramadol HCl Tablets:

CorePharma, LLC
215 Wood Avenue
Middlesex, NJ 08846
CFN: 2249375

[redacted]

BIO STUDY

Bio is acceptable (11/19/01) per M. Makari.

The dissolution will be conducted as follows:

Apparatus USP Type II [redacted]

15 min [redacted]
60 min [redacted]
180 min [redacted]

VALIDATION

Acetaminophen [redacted] Raw Material is compendial. Acetaminophen [redacted] Raw Material contains Acetaminophen USP. The drug product is

manufacturing process

Redacted 4

Page(s) of trade secret and /or confidential commercial information

Guidance are included (p. 2985-2994, Am: 2/5/02, p. 7-14).

Stability specifications (Am: 12/7/01, p. 29-36, Am: 2/5/02, p. 6-13):

Test	Method	Limit
Package integrity		Satisfactory
Appearance		White capsule shaped film coated tablets. Debossed "cor 116" on one side and plain on the other side.
Odor		Characteristic
Weight variation		731 mg - 809 mg
Dissolution		in 15 min in 60 min NLT in 180 min
Assay		
Impurity assay Individual unknown Total		NMT [NMT NMT NMT [NMT NMT [NMT
		NMT

Expiration date: 24 months based on accelerated stability data.

LABELING

Acceptable per C. Park (12/21/01).

STERILIZATION VALIDATION (IF APPLICABLE)

N/A

SIZE OF BIO/STABILITY BATCHES

Exhibit batch: Lot #CR0012, tablets.

PROPOSED PRODUCTION BATCH

The commercial batch size of tablets is within the scale-up rule.

CHEMIST: Mayra L. Piñeiro-Sánchez, Ph.D. DATE: February 20, 2002
SUPERVISOR: Glen Smith DATE: February 21, 2002

MS 3/14/02

V:\FIRMSam\CorePhar\LTRS&REV\76200.TAPSUM

1. CHEMISTRY REVIEW NO. 1

2. ANDA # 76-200

3. NAME AND ADDRESS OF APPLICANT
CorePharma LLC
Attention: Mukteeshwar Gande, M.S., R.Ph.
215 Wood Avenue
Middlesex, NJ 08846

4. LEGAL BASIS FOR SUBMISSION
Tylenol® Arthritis Pain Caplets - NDA #19-872
MacNeil

The applicant submitted a paragraph IV certification for the for the following patents:

No. 4820522	Exp. 7/27/07
No. 4968509	Exp. 11/6/07
No. 5004613	Exp. 7/27/07

There is no unexpired exclusivity for this product.

5. SUPPLEMENT(s) N/A

6. PROPRIETARY NAME
N/A

7. NONPROPRIETARY NAME
Acetaminophen Extended Release Tablets 650 mg

8. SUPPLEMENT(s) PROVIDE(s) FOR: N/A

9. AMENDMENTS AND OTHER DATES:
July 2, 2001 Original Submission
July 30, 2001 New Correspondence

10. PHARMACOLOGICAL CATEGORY
Analgesic

11. Rx or OTC
Rx

12. RELATED IND/NDA/DMF(s)
NDA #19-872 RLD
DMF [redacted]
DMF [redacted]
DMF [redacted]
DMF [redacted]
DMF [redacted]
DMF [redacted]
DMF [redacted]

DMF [redacted]
DMF [redacted]
DMF [redacted]
DMF [redacted]
DMF [redacted]

13. DOSAGE FORM
Tablet, oral

14. POTENCIES
650 mg

15. CHEMICAL NAME AND STRUCTURE

Acetaminophen



Acetamide, *N*-(4'-hydroxyphenyl)-, 4'-hydroxyacetanilide
$C_8H_9NO_2$ FW = 151.16

16. RECORDS AND REPORTS

August 1, 2001	Receipt acknowledged
August 14, 2001	Labeling review #1
September 25, 2001	Chemistry review #1

17. COMMENTS
Chemistry is deficient.
Bioequivalence is acceptable (11/19/01)
Labeling is deficient
DMFs for APIs are adequate
EER is acceptable (11/13/01)
Methods will be send to a FDA lab.

18. CONCLUSIONS AND RECOMMENDATIONS
The application is not recommended for approval. MINOR.

19. REVIEWER:
Mayra L. Piñeiro-Sánchez, Ph.D.

DATE COMPLETED:
September 25, 2001

Redacted 20

Page(s) of trade secret and /or confidential commercial information

1. CHEMISTRY REVIEW NO. 2

2. ANDA # 76-200

3. NAME AND ADDRESS OF APPLICANT
CorePharma LLC
Attention: Mukteeshwar Gande, M.S., R.Ph.
215 Wood Avenue
Middlesex, NJ 08846

4. LEGAL BASIS FOR SUBMISSION
Tylenol® Arthritis Pain Caplets - NDA #19-872
MacNeil

The applicant submitted a paragraph IV certification for the for the following patents:

No. 4820522	Exp. 7/27/07
No. 4968509	Exp. 11/6/07
No. 5004613	Exp. 7/27/07

There is no unexpired exclusivity for this product.

5. SUPPLEMENT(s) N/A

6. PROPRIETARY NAME
N/A

7. NONPROPRIETARY NAME
Acetaminophen Extended Release Tablets 650 mg

8. SUPPLEMENT(s) PROVIDE(s) FOR: N/A

9. AMENDMENTS AND OTHER DATES:
July 2, 2001 Original Submission
July 30, 2001 New Correspondence
December 7, 2001 Minor Amendment (Chem., Label., Bio.)
February 5, 2002 Telephone amendment Chemistry

10. PHARMACOLOGICAL CATEGORY
Analgesic

11. Rx or OTC
Rx

12. RELATED IND/NDA/DMF(s)
NDA #19-872 RLD
DMF # [redacted]
DMF # [redacted]
DMF # [redacted]
DMF # [redacted]
DMF # [redacted]

DMF #
DMF #
DMF #
DMF #
DMF #
DMF
DMF

13. DOSAGE FORM
Tablet, oral

14. POTENCIES
650 mg

15. CHEMICAL NAME AND STRUCTURE

Acetaminophen



Acetamide, *N*-(4'-hydroxyphenyl)-, 4'-hydroxyacetanilide
$C_8H_9NO_2$ FW = 151.16

16. RECORDS AND REPORTS

August 1, 2001	Receipt acknowledged
August 14, 2001	Labeling review #1
September 25, 2001	Chemistry review #1
December 21, 2001	Labeling review #2

17. COMMENTS
Chemistry is acceptable.
Bioequivalence is acceptable (11/19/01)
Labeling is acceptable (12/21/01)
DMFs for APIs are adequate
EER is acceptable (11/13/01)
Methods sent to Diane O'Brien on 2/5/02.

18. CONCLUSIONS AND RECOMMENDATIONS
The application is recommended for approval with a commitment to address any concerns from the field regarding the method validation.

19. REVIEWER:
Mayra L. Piñeiro-Sánchez, Ph.D.

DATE COMPLETED:
February 6, 2002

Redacted 20

Page(s) of trade secret and /or confidential commercial information